Latest Research Roadmap of Approved Drugs & Vaccines for Covid-19 Recovery

Pallavi S Shelke¹*, Prafulla P Adkar², Nikita S Kolte³, Surekha N Shegar⁴, Anirudha V Nilangekar⁵, Swapnil B

Gadekar⁶, Anuradha M Patil⁷ and Komal L Bhosale⁸

Published: August 30, 2022

DOI: 10.55162/MCMS.03.064

View Pdf

Abstract  

     The coronavirus disease 2019 (COVID-19) pandemic caused and is still causing significant mortality and economic consequences all over the globe. Till date today, there are four U.S Food and Drug administration (FDA) approved vaccines, Pfizer-BioNTech, Moderna, Janssen and Novavax COVID-19 vaccines. Also, the antiviral drug remdesivir and two combinations of monoclonal antibody treatments are authorized for Emergency use (EUA) in certain patients. Furthermore, baricitinib- immune modulator was approved in Japan (April 23, 2021) for certain hospitalized adults with covid-19. Despite available vaccines and EUA, pharmacological therapy for the prevention and treatment of COVID-19 is still highly required. There are several ongoing clinical trials investigating the efficacy of clinically available drugs in treating COVID-19. In this review, latest novel pharmacological agents for the possible treatment of COVID-19 will be discussed.
     COVID-19 vaccine is the most promising strategy to end the current pandemic in addition to anti- viral agents. Design of novel anti-viral agents which are specific for SARS-CoV-2 will provide more effective therapy for COVID-19 patients. Development of effective vaccines and anti-viral drugs both needs multidisciplinary cooperation. Before effective antiviral drugs for COVID-19 are available, current treatment options will come from repurposing drugs. Thus, in this review we aim to highlight potential therapeutic strategies from the viewpoints of clinicians based on updated clinical evidences, and provide a basis for future researches of effective antiviral therapies. In the future, the development of new drugs and vaccines relies on multidisciplinary cooperation among structural biologists, chemists, and medical doctors. A knowledge gap of pharmacology for COVID-19 is expected to be filled up.

.